-
Zolbetuximab for Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Zolbetuximab for Injection (trade name: 威络益/VYLOY) of Astellas Pharma Europe B.V. is approved for marketing by China NMPA.
-
Tagitanlimab Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Tagoliticimab Injection (trade name: 科泰莱) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Amimestrocel Injection Approved with Conditions for Marketing by China NMPA
2025-06-11
Recently, the Amimestrocel Injection (trade name: 睿铂生) of Platinumlife Biotechnology (Beijing) Co., Ltd. is approved with conditions through the priority review and approval procedure by China NMPA.
-
Innovative TCM Xiao’er Huangjin Zhike Granules Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1.1 innovative traditional Chinese medicine (TCM) Xiao' er Huangjin Zhike Granules of Beijing Dongfang Yunjia Pharmaceutical Co., Ltd. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Recaticimab for Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Recaticimab for Injection (trade name: 艾心安) of Guangdong Hengrui Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Prusogliptin Tablets Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1 innovative drug Prusogliptin Tablets (trade name: 善泽平) of CSPC OUYI PHARMACEUTICAL CO., LTD. is approved for marketing by China NMPA.
